Industry News
Biotechnology Industry News
The FDA has pulled a U-turn on…
The FDA has pulled a U-turn on uniQure’s Huntington’s disease gene therapy, giving the biotech the OK to file for accelerated approval after previously demanding data from another trial.
Vedana Therapeutics has emerged…
Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s subcutaneously delivered antibodies for migraine prevention.
Jazz Pharmaceuticals is looking to…
Jazz Pharmaceuticals is looking to bolster its oncology research bona fides via a partnership with AbCellera to discover and develop T-cell-engaging (TCE) antibodies that could result in up to $820 million in biobucks for each
With a panel of outside experts…
With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its contender for the United States’ first mRNA-based influenza vaccine are
Eli Lilly is taking another shot…
Eli Lilly is taking another shot at the pain market, continuing a recent M&A binge that shows no signs of slowing down.
Explore how FDA Breakthrough…
Explore how FDA Breakthrough Therapy and RMAT designations can create opportunities for oncology programs when backed by the right development strategy.
As biopharma companies of all…
As biopharma companies of all stripes devote more time and attention to AI-based drug discovery and development, healthcare PE firm Altaris is bolstering its presence in the field through M&A.
John Tsai, M.D., is rounding out…
John Tsai, M.D., is rounding out his global drug development resume. Immediately after landing at Daiichi Sankyo, the pharma veteran finds himself leading the R&D portion of the antibody-drug conjugate specialist’s new five-year plan, which
Edgewise Therapeutics has reported…
Edgewise Therapeutics has reported phase 2 data on its cardiomyopathy prospect, keeping the biotech on track to start pivotal development of a would-be challenger to Bristol Myers Squibb and Cytokinetics.
AI drug design specialist…
AI drug design specialist Protillion has inked a $510 million biobucks collaboration and license agreement with Merck & Co. that brings together Protillion’s platform and Merck’s drug discovery expertise.
Adaptive Biotechnologies is…
Adaptive Biotechnologies is planning to separate its drug discovery and diagnostics businesses, outlining its intent to evaluate “strategic and structural alternatives” for the medicine wing of the company
The company’s SPY002 prompted a…
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients’ Robart’s Histopathology Index (RHI) scores by week 12.
Nature Index’s latest research…
Nature Index’s latest research rankings show that China continues to be the clear leader in contributions to scientific journals, with a 22% increase between 2024 and 2025. While China remains well ahead of the rest
A federal jury in Delaware has…
A federal jury in Delaware has found that Amgen and its acquired Teneobio willfully infringed on an antibody patent held by Harbour Antibodies, a Dutch subsidiary of China’s Harbour BioMed.
Six weeks after Intellia…
Six weeks after Intellia Therapeutics reported that it met its primary endpoint in a phase 3 trial of its in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) for patients with hereditary angioedema (HAE), the company released
U.K. regulators have issued a…
U.K. regulators have issued a “negative review” of Traws Pharma’s planned human influenza challenge study, forcing the biotech to defer a phase 2a trial tied to $20 million in funding.
Neumora’s navacaprant has…
Neumora's navacaprant has completed a clean sweep of trial misses in major depressive disorder.
Soligenix has scrapped its…
Soligenix has scrapped its cutaneous T-cell lymphoma program in the wake of a phase 3 setback, leaving the biotech focused on another rare disease prospect and considering strategic alternatives.
Eli Lilly’s up-to-$2.3 billion…
Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet.
Elon Musk’s SpaceX may be igniting…
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week.